Neoteryx delivers on the promise of blood microsampling innovation. We are focused on delivering simple, quantitative microsampling solutions for biological samples, amenable to downstream automation. Our customers work to advance pharmaceutical development, personalized medicine, biotechnology research and clinical diagnostics.Who is Neoteryx? | Video
Our class I exempt medical device, The Mitra® microsampler, is based on Volumetric Absorptive Microsampling (VAMS™) technology. It facilitates convenient specimen collection and transportation of blood and other biological fluids to improve animal and patient welfare, reduce laboratory costs, and enable new value-based, patient-centered models of care.
Incubated at Phenomenex for four years, the research and development of Volumetric Absorptive Microsampling (VAMS™) technology occurred with the cooperation of global pharmaceutical companies. VAMS simplifies the collection, storage, and transportation of blood samples through the instrument known as the Mitra® Microsampling Device, introduced by Neoteryx in 2014. Mitra devices accurately collect microliters of biological fluid in seconds, without volumetric blood hematocrit bias.
A chat over the limitations of Dried Blood Spot (DBS) cards between Dr. James Rudge (Phenomenex) and Dr. Neil Spooner (GlaxoSmithKline) reveals the market potential for a next generation dried blood microsampling technology.
10 µL devices based on VAMS™ technology are thoroughly tested by five leading pharmaceutical organizations, validating that they collect fixed volumes of blood while eliminating the volumetric hematocrit bias associated with DBS cards. Neoteryx is born!
As a CE-IVD registered device, Neoteryx is prepared to introduce the in vitro diagnostic European market to next generation dried blood collection and transportation.
Neoteryx expands into the United Kingdom to better serve its growing European customer base.
Manufacturing expands into a new building - Neo 2 - to better accommodate the growing need to manufacture more of this technology.
With the release of the 30 µL tips, users of Mitra® devices now collect more blood. This facilitates detection of analytes with low blood concentrations and multiplex analyses from one sampler tip.
At only five years old, VAMS™ rides a wave of commercial and academic interest to rack up its 65th publication.